Daiichi Sankyo Co Ltd (TSE:4568)
円 5531 49 (0.89%) Market Cap: 10.61 Til Enterprise Value: 9.48 Til PE Ratio: 52.87 PB Ratio: 6.29 GF Score: 93/100

Daiichi Sankyo Co Ltd R&D Day Transcript

Dec 11, 2023 / 08:00AM GMT
Release Date Price: 円4140 (+3.76%)
Sunao Manabe
Daiichi Sankyo Company, Limited - Group CEO & Executive Chairperson

[Interpreted] I am Manabe. Thank you for joining us today at Daiichi Sankyo's R&D Day.

This fiscal year, we have updated our R&D strategy from 3 and Alpha to 5DXd ADCs and Next Wave in line with the strong progress of our pipeline. In particular, the expansion of the ENHERTU indications has progressed very well, and we have also received clinically meaningful clinical trial data for the other 4, 5 DXd ADCs assets, making it a very productive year.

We have been accumulating positive data for ENHERTU and Dato-DXd with a view to expanding other indications, or obtaining regulatory approval and under the strong collaboration with AstraZeneca that we have established to date. We will continue to pursue the maximization of product values. For HER3-DXd DS-7300 and DS-6000. The accumulation of favorable data has further enhanced the potential and moved them to the stage. We plan to maximize the product value. In addition to these changes in our internal environment, externally, competition of ADC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot